WO2017210246A3 - Conjugués de pénicillamine et particules et formulations associées - Google Patents

Conjugués de pénicillamine et particules et formulations associées Download PDF

Info

Publication number
WO2017210246A3
WO2017210246A3 PCT/US2017/035107 US2017035107W WO2017210246A3 WO 2017210246 A3 WO2017210246 A3 WO 2017210246A3 US 2017035107 W US2017035107 W US 2017035107W WO 2017210246 A3 WO2017210246 A3 WO 2017210246A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
particles
formulations
penicillamine
methods
Prior art date
Application number
PCT/US2017/035107
Other languages
English (en)
Other versions
WO2017210246A2 (fr
Inventor
Brian H. White
Benoît MOREAU
Patrick Rosaire BAZINET
Mark T. Bilodeau
Original Assignee
Tarveda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarveda Therapeutics, Inc. filed Critical Tarveda Therapeutics, Inc.
Publication of WO2017210246A2 publication Critical patent/WO2017210246A2/fr
Publication of WO2017210246A3 publication Critical patent/WO2017210246A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des conjugués d'un agent actif attaché à une fraction de ciblage par l'intermédiaire d'un lieur de pénicillamine, et des particules comprenant de tels conjugués. Ces conjugués et particules peuvent conférer une stabilité accrue et permettre une administration spatiotemporelle améliorée de l'agent actif, une biodistribution et une pénétration améliorées dans la tumeur, et/ou une toxicité réduite. L'invention concerne des procédés de préparation des conjugués, des particules et de leurs formulations. L'invention concerne en outre des procédés d'administration des formulations à un sujet en ayant besoin, par exemple, pour traiter ou prévenir un cancer.
PCT/US2017/035107 2016-05-31 2017-05-31 Conjugués de pénicillamine et particules et formulations associées WO2017210246A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343445P 2016-05-31 2016-05-31
US62/343,445 2016-05-31

Publications (2)

Publication Number Publication Date
WO2017210246A2 WO2017210246A2 (fr) 2017-12-07
WO2017210246A3 true WO2017210246A3 (fr) 2017-12-28

Family

ID=60479055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/035107 WO2017210246A2 (fr) 2016-05-31 2017-05-31 Conjugués de pénicillamine et particules et formulations associées

Country Status (1)

Country Link
WO (1) WO2017210246A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
AU2018386218A1 (en) * 2017-12-14 2020-07-02 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
CN108440664A (zh) * 2018-03-27 2018-08-24 上海欣科医药有限公司 一种用于癌症检测的生长抑素类似物及其制备方法和应用
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
PE20221005A1 (es) * 2019-07-11 2022-06-15 Sun Pharma Advanced Res Co Ltd Derivados de la camptotecina
WO2022035843A1 (fr) * 2020-08-12 2022-02-17 Nanomedicine Innovation Center, Llc Inhibiteurs de topoisomérase
US20230407169A1 (en) * 2020-11-12 2023-12-21 Soochow University Red-light-mediated nucleic acid anchoring-type fluorescent probe, and preparation method therefor and use thereof
CN113307754A (zh) * 2021-06-01 2021-08-27 上海吉奉生物科技有限公司 一种l-青霉胺盐酸盐的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283264A1 (en) * 2013-02-07 2015-10-08 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
WO2016004048A2 (fr) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Conjugués ciblés, particules et préparations associées

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283264A1 (en) * 2013-02-07 2015-10-08 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
WO2016004048A2 (fr) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Conjugués ciblés, particules et préparations associées

Also Published As

Publication number Publication date
WO2017210246A2 (fr) 2017-12-07

Similar Documents

Publication Publication Date Title
WO2017210246A3 (fr) Conjugués de pénicillamine et particules et formulations associées
WO2016004048A3 (fr) Conjugués ciblés, particules et préparations associées
MX2019004963A (es) Conjugados y particulas especificos del sstr y formulaciones de los mismos.
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
MX2015008503A (es) Conjugados dirigidos encapsulados en particulas y sus formulaciones.
MX2022001540A (es) Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia.
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015095227A3 (fr) Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
WO2016161342A3 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
WO2016046793A3 (fr) Conjugués radiopharmaceutiques
NZ745069A (en) Pyrrolobenzodiazepines and conjugates thereof
SG11201808167VA (en) Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2014194030A3 (fr) Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
WO2016210376A3 (fr) Peptides thérapeutiques et leurs procédés d'utilisation
WO2011002852A3 (fr) Complexes de pro-médicaments et leurs procédés d'utilisation
PH12017502392A1 (en) Targeted conjugates and particles and formulations thereof
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
WO2015114166A3 (fr) Conjugués médicamenteux ciblés
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
WO2010136168A3 (fr) Administration continue de ligands d'intégrines pour le traitement du cancer
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
WO2016130800A3 (fr) Compositions pharmaceutiques comprenant des dérivés d'alcool périllylique
WO2019147338A3 (fr) Produits radiopharmaceutiques et leurs procédés d'utilisation
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17807369

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17807369

Country of ref document: EP

Kind code of ref document: A2